SCHEMBL2276797

SCHEMBL2276797

O=C(Nc1cc(CCc2ccc3occc3c2)ccc1C(=O)O)c1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTC4S Q16873 1/20 0.49
KMT2A Q03164 4/20 0.49
MEN1 O00255 3/20 0.49
PKM P14618 3/20 0.49
MAPT P10636 1/20 0.49
GRIK1 P39086 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
CTNNB1 P35222 1/20 0.46
WNT3A P56704 1/20 0.46
NPC1 O15118 1/20 0.45
MAOB P27338 1/20 0.45
RAB9A P51151 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
FABP3 P05413 1/20 0.43
FABP4 P15090 1/20 0.43
FABP5 Q01469 1/20 0.43
PLK1 P53350 6/20 0.43
PLK3 Q9H4B4 4/20 0.43
DHODH Q02127 1/20 0.43
MCL1 Q07820 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2270959 0.91 CTNNB1 (0.47) MAPTCTNNB1WNT3APLK1PLK3
SCHEMBL2272559 0.85 ACLY (0.57) KMT2AMEN1PKMMAPTGRIK1
SCHEMBL2275929 0.83 KMT2A (0.62) LTC4SKMT2AMEN1PKMMAPT
SCHEMBL2271146 0.82 PYGM (0.54) KMT2AMEN1PKMMAPTGRIK1
SCHEMBL2269542 0.82 MEN1 (0.49) LTC4SKMT2AMEN1PKMMAPT
SCHEMBL2269539 0.82 MEN1 (0.49) LTC4SKMT2AMEN1PKMMAPT
SCHEMBL4217800 0.80 MEN1 (0.49) KMT2AMEN1MAPTTDP1CTNNB1
SCHEMBL2278451 0.79 LTC4S (0.60) LTC4SKMT2AMEN1PKMMAPT
SCHEMBL2272399 0.79 ACLY (0.59) KMT2AMEN1PKMMAPTGRIK1
SCHEMBL2271080 0.78 MEN1 (0.56) LTC4SKMT2AMEN1PKMMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP26, MMP11 LTC4S 2518/4885KMT2A 1669/4885MEN1 3105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.